“Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s599. doi:10.25251/y4a30r91.